Insulin drug makers reject antitrust claims in MDL

Law360 (July 12, 2021, 5:34 p.m. EDT) – Novo Nordisk Inc., CVS Health Corp. and other drugmakers and pharmacy benefit managers partially secured their offer to evade claims, at least for now, that they colluded to jack up the prices of insulin drugs after a New Jersey federal judge said the allegations that direct buyers paid inflated prices were not sufficient to substantiate the buyers’ antitrust claim.

U.S. District Judge Brian Martinotti, who dismissed the antitrust complaint without prejudice on Friday, agreed that drug wholesalers FWK Holdings LLC and Professional Drug Co. Inc. did not have the status of association to assert a complaint for prejudice against defendants under section 2 (c) of the Robinson -Patman Act. Antitrust …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!

TRY LAW360 FREE FOR SEVEN DAYS

Source link